NCT05665738
Two-fraction HDR Monotherapy for Localized Prostate Cancer
Recruiting
NAAges 18+InterventionalTreatmentUniversity of California, San FranciscoInvestigator-initiated
~17 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:High Dose Rate Monotherapy
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants with treatment-related adverse events
Measured over Up to 6 months
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- I-Chow Hsu, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants with treatment-related adverse eventsUp to 6 months
The proportion of participants with reported grade 3 or higher genitourinary (GU) or gastrointestinal (GI) toxicities, as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported.